The platform enables specific modulation of mTORC1, the gatekeeper of cellular metabolism and renewal, to address the diseases processes that underlie age-related diseases such as chronic kidney diseases.
Our scientists have made a breakthrough discovery related to mTORC1 inhibitors. Navitor’s proprietary Navalogs are a new and fully selective class of mTORC1 inhibitors that allow for an entirely new approach to the treatment of diseases linked to increased mTORC1 activity.
Our lead Navalog, NV-20494 is a kidney-directed fully selective mTORC1 inhibitor that has broad potential in kidney diseases, including autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy, and acute kidney injury.
Navitor is also leveraging its Navalog chemistry to discover a new class of compounds that are optimized for brain exposure for the treatment of familial focal epilepsy and neurodegenerative diseases.